Dysregulated biosynthesis and hydrolysis of cyclic-di-adenosine monophosphate impedes sporulation and butanol and acetone production in Clostridium beijerinckii NCIMB 8052.
Marian M Awaga-Cromwell, Santosh Kumar, Hieu M Truong, Eric Agyeman-Duah, Christopher C Okonkwo, Victor C Ujor
{"title":"Dysregulated biosynthesis and hydrolysis of cyclic-di-adenosine monophosphate impedes sporulation and butanol and acetone production in <i>Clostridium beijerinckii</i> NCIMB 8052.","authors":"Marian M Awaga-Cromwell, Santosh Kumar, Hieu M Truong, Eric Agyeman-Duah, Christopher C Okonkwo, Victor C Ujor","doi":"10.3389/fbioe.2025.1547226","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Although solventogenic <i>Clostridium</i> species (SCS) produce butanol, achieving high enough titers to warrant commercialization of biobutanol remains elusive. Thus, deepening our understanding of the intricate cellular wiring of SCS is crucial to unearthing new targets and strategies for engineering novel strains capable of producing and tolerating greater concentrations of butanol.</p><p><strong>Methods: </strong>This study investigated the potential role of cyclic-di-adenosine monophosphate (c-di-AMP) in regulating solvent biosynthesis in <i>C. beijerinckii</i> NCIMB 8052. Genes for c-di-AMP-producing and degrading enzymes [DNA integrity scanning protein A (<i>disA</i>) and phosphodiesterase (<i>pde</i>), respectively] were cloned in this organism and the recombinant strains were characterized relative to the control strain.</p><p><strong>Results: </strong>Plasmid-borne expression of disA in <i>C. beijerinckii</i> led to a 1.83-fold increase in c-di-AMP levels and near complete (∼100%) inhibition of butanol and acetone biosynthesis. Conversely, c-di-AMP concentrations in the pde-expressing strain reduced 7.54-fold relative to the control with 4.20- and 2.3-fold reductions in butanol and acetone concentrations, respectively, when compared to the control strain. Relative to the control and the <i>pde</i>-expressing strains, the <i>disA</i>-expressing strain produced 1.50- and 1.90-fold more ethanol, respectively. Enzyme activity assays show that core solvent biosynthesis enzymes are mostly inhibited <i>in vitro</i> by exogenously supplemented c-di-AMP (50 nM). Both recombinant strains of <i>C. beijerinckii</i> are impaired for sporulation, particularly the <i>disA</i>-expressing strain.</p><p><strong>Discussion: </strong>Collectively, the results show that dysregulated production and hydrolysis of c-di-AMP severely impair butanol and acetone biosynthesis in <i>C. beijerinckii</i>, suggesting broader roles of this second messenger in the regulation of solventogenesis and likely, sporulation in this organism.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1547226"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906698/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1547226","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Although solventogenic Clostridium species (SCS) produce butanol, achieving high enough titers to warrant commercialization of biobutanol remains elusive. Thus, deepening our understanding of the intricate cellular wiring of SCS is crucial to unearthing new targets and strategies for engineering novel strains capable of producing and tolerating greater concentrations of butanol.
Methods: This study investigated the potential role of cyclic-di-adenosine monophosphate (c-di-AMP) in regulating solvent biosynthesis in C. beijerinckii NCIMB 8052. Genes for c-di-AMP-producing and degrading enzymes [DNA integrity scanning protein A (disA) and phosphodiesterase (pde), respectively] were cloned in this organism and the recombinant strains were characterized relative to the control strain.
Results: Plasmid-borne expression of disA in C. beijerinckii led to a 1.83-fold increase in c-di-AMP levels and near complete (∼100%) inhibition of butanol and acetone biosynthesis. Conversely, c-di-AMP concentrations in the pde-expressing strain reduced 7.54-fold relative to the control with 4.20- and 2.3-fold reductions in butanol and acetone concentrations, respectively, when compared to the control strain. Relative to the control and the pde-expressing strains, the disA-expressing strain produced 1.50- and 1.90-fold more ethanol, respectively. Enzyme activity assays show that core solvent biosynthesis enzymes are mostly inhibited in vitro by exogenously supplemented c-di-AMP (50 nM). Both recombinant strains of C. beijerinckii are impaired for sporulation, particularly the disA-expressing strain.
Discussion: Collectively, the results show that dysregulated production and hydrolysis of c-di-AMP severely impair butanol and acetone biosynthesis in C. beijerinckii, suggesting broader roles of this second messenger in the regulation of solventogenesis and likely, sporulation in this organism.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
